Can BioTAK Identify Broken Heart Syndrome?
Blood biomarkers may support diagnosis before invasive coronary angiography
Clinical Scorecard: Can BioTAK Identify Broken Heart Syndrome?
At a Glance
Category Detail
Condition Takotsubo syndrome (broken heart syndrome) Key Mechanisms Temporary dysfunction of the left ventricle, resembling acute coronary syndrome. Target Population Patients presenting with chest pain and elevated cardiac biomarkers. Care Setting Clinical diagnostic pathway for distinguishing takotsubo syndrome from acute coronary syndrome.
Key Highlights
BioTAK score developed using data from 3,615 patients. Achieved an area under the curve of 0.97 in the development cohort. Score uses four biomarkers and patient sex for diagnosis. High sensitivity (95.7%) for scores below 27 indicating low probability of takotsubo syndrome. Not intended to replace urgent coronary angiography in high-risk patients. Guideline-Based Recommendations
Diagnosis
Use BioTAK score to distinguish takotsubo syndrome from acute coronary syndrome. Management
Consider BioTAK score in stable patients without ST-segment elevation. Monitoring & Follow-up
Further validation needed to assess impact on angiography and patient outcomes. Risks
Laboratory availability for sLOX-1 and PAM assays is currently limited. Patient & Prescribing Data
Patients with suspected takotsubo syndrome or acute coronary syndrome.
BioTAK score may support assessment when reliable history-taking is difficult.
Clinical Best Practices
Utilize objective laboratory and demographic data for diagnosis. Validate BioTAK score in independent cohorts. Related Resources & Content
